First daily pill for endometriosis approved for NHS use
Today we've recommended the first long-term daily pill to treat endometriosis that could transform how this painful condition is managed.
Today we've recommended the first long-term daily pill to treat endometriosis that could transform how this painful condition is managed.
Cost and evidence gaps remain barriers to approving funding in the NHS for donanemab and lecanemab.
NICE publishes final draft guidance recommending efanesoctocog alfa as an option for treating and preventing bleeding in people aged 2 and over with severe haemophilia A.
Today we've recommended an immunotherapy treatment that could prevent blood cancer from returning in adults who've responded well to initial therapy.
An end of year summary from our chief executive, Dr Sam Roberts.
A guide to the severity modifier and how it is leading to more positive recommendations overall from NICE.
Introducing the Medicines and Medical Devices Access Initiative (MMD): a new collaboration that aims to improve patient access to safe, clinically and cost-effective healthcare products.
Understand why we're prioritising key topic areas for evaluation and what it means for innovators